Cargando…

Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide

Didecyldimethylammonium bromide (DDAB) is a fourth generation dialkyl-quaternary ammonium compound (QAC) that is used in numerous products for its antimicrobial properties. While many QACs have been associated with allergic disease, the toxicity and sensitization of DDAB have not been thoroughly inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shane, Hillary L., Lukomska, Ewa, Stefaniak, Aleksandr B., Anderson, Stacey E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391722/
https://www.ncbi.nlm.nih.gov/pubmed/29124973
http://dx.doi.org/10.1080/1547691X.2017.1397826
_version_ 1783398354191908864
author Shane, Hillary L.
Lukomska, Ewa
Stefaniak, Aleksandr B.
Anderson, Stacey E.
author_facet Shane, Hillary L.
Lukomska, Ewa
Stefaniak, Aleksandr B.
Anderson, Stacey E.
author_sort Shane, Hillary L.
collection PubMed
description Didecyldimethylammonium bromide (DDAB) is a fourth generation dialkyl-quaternary ammonium compound (QAC) that is used in numerous products for its antimicrobial properties. While many QACs have been associated with allergic disease, the toxicity and sensitization of DDAB have not been thoroughly investigated. The purpose of these studies was to evaluate the irritancy and sensitization potential of DDAB following dermal application in a murine model. DDAB induced significant irritancy (0.0625–2%), evaluated by ear swelling in female BALB/c mice. Initial evaluation of the sensitization potential was conducted using the local lymph node assay (LLNA) at concentrations ranging from 0.0625% to 2%. A concentration-dependent increase in lymphocyte proliferation was observed with a calculated EC3 value of 0.057%. Immune cell phenotyping along with local and systemic IgE levels were evaluated following 4 and 14 days of dermal application. Phenotypic analyses revealed significant and dose-responsive increases in the absolute number of B-cells, CD4(+) T-cells, CD8(+) T-cells, and dendritic cells in the draining lymph nodes (DLNs) following 4 and 14 days of dermal exposure with significant increases in the number of activated B-cells and dendritic cells. However, increased activation of CD4(+) T-cell and CD8(+) T-cells was only observed following four days of DDAB exposure. Exposure to DDAB also induced increased production of IgE as evaluated by phenotypic analysis of DLN B-cells (IgE(+) B-cells) and measurement of total serum IgE levels following 14 days but not four days of dermal application. Significant increases in gene expression were observed in the DLN (Il-4, Il-10, and ox40l) and ear (tslp) following 4 and 14 days of DDAB exposure. These results demonstrate the potential for development of irritation and hypersensitivity responses to DDAB following dermal exposure and raise concerns about the effects of exposure duration on hypersensitivity responses.
format Online
Article
Text
id pubmed-6391722
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-63917222019-02-27 Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide Shane, Hillary L. Lukomska, Ewa Stefaniak, Aleksandr B. Anderson, Stacey E. J Immunotoxicol Article Didecyldimethylammonium bromide (DDAB) is a fourth generation dialkyl-quaternary ammonium compound (QAC) that is used in numerous products for its antimicrobial properties. While many QACs have been associated with allergic disease, the toxicity and sensitization of DDAB have not been thoroughly investigated. The purpose of these studies was to evaluate the irritancy and sensitization potential of DDAB following dermal application in a murine model. DDAB induced significant irritancy (0.0625–2%), evaluated by ear swelling in female BALB/c mice. Initial evaluation of the sensitization potential was conducted using the local lymph node assay (LLNA) at concentrations ranging from 0.0625% to 2%. A concentration-dependent increase in lymphocyte proliferation was observed with a calculated EC3 value of 0.057%. Immune cell phenotyping along with local and systemic IgE levels were evaluated following 4 and 14 days of dermal application. Phenotypic analyses revealed significant and dose-responsive increases in the absolute number of B-cells, CD4(+) T-cells, CD8(+) T-cells, and dendritic cells in the draining lymph nodes (DLNs) following 4 and 14 days of dermal exposure with significant increases in the number of activated B-cells and dendritic cells. However, increased activation of CD4(+) T-cell and CD8(+) T-cells was only observed following four days of DDAB exposure. Exposure to DDAB also induced increased production of IgE as evaluated by phenotypic analysis of DLN B-cells (IgE(+) B-cells) and measurement of total serum IgE levels following 14 days but not four days of dermal application. Significant increases in gene expression were observed in the DLN (Il-4, Il-10, and ox40l) and ear (tslp) following 4 and 14 days of DDAB exposure. These results demonstrate the potential for development of irritation and hypersensitivity responses to DDAB following dermal exposure and raise concerns about the effects of exposure duration on hypersensitivity responses. 2017-12 /pmc/articles/PMC6391722/ /pubmed/29124973 http://dx.doi.org/10.1080/1547691X.2017.1397826 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Shane, Hillary L.
Lukomska, Ewa
Stefaniak, Aleksandr B.
Anderson, Stacey E.
Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title_full Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title_fullStr Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title_full_unstemmed Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title_short Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
title_sort divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391722/
https://www.ncbi.nlm.nih.gov/pubmed/29124973
http://dx.doi.org/10.1080/1547691X.2017.1397826
work_keys_str_mv AT shanehillaryl divergenthypersensitivityresponsesfollowingtopicalapplicationofthequaternaryammoniumcompounddidecyldimethylammoniumbromide
AT lukomskaewa divergenthypersensitivityresponsesfollowingtopicalapplicationofthequaternaryammoniumcompounddidecyldimethylammoniumbromide
AT stefaniakaleksandrb divergenthypersensitivityresponsesfollowingtopicalapplicationofthequaternaryammoniumcompounddidecyldimethylammoniumbromide
AT andersonstaceye divergenthypersensitivityresponsesfollowingtopicalapplicationofthequaternaryammoniumcompounddidecyldimethylammoniumbromide